Health Care Research on Societal Costs of Prescription Opioid Abuse Featured in Nature
July 02, 2015
Research conducted by a team of Analysis Group health care consultants into the societal cost savings of a prescription opioid formulation with abuse-deterrent properties was featured in a recent Nature technology article, "Barriers to Misuse" (June 25, 2015). In the article, Nature explored the misuse and abuse of prescription opioids and highlighted several steps that have been taken by pharmaceutical manufacturers to make these drugs more resistant to tampering. The article cited research conducted by Analysis Group Vice President Noam Kirson, Managing Principal Alan White, Principal Howard Birnbaum, and Manager Amie Shei.
The research, "Societal Economic Benefits Associated with an Extended-Release Opioid with Abuse-Deterrent Technology in the United States" (Pain Medicine, September 2014), was conducted in conjunction with colleagues from Purdue Pharma, the College of William and Mary, and Harvard Medical School. The authors estimated potential cost savings from a societal perspective, including direct medical costs and indirect costs for caregivers, the workplace, and the criminal justice system.
Read the Pain Medicine research study
Read the related Nature article